Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology
Eur J Intern Med. 2022 Apr 22:S0953-6205(22)00142-X. doi: 10.1016/j.ejim.2022.04.006. Online ahead of print.ABSTRACTRenin-angiotensin-aldosterone system (RAAS) inhibition is a mainstay of the pharmacological treatment of heart failure with reduced ejection fraction (HFrEF). In the last years RAAS blockade has been improved by the introduction of the Angiotensin Receptor-Neprilysin Inhibitor (ARNI) sacubitril/valsartan, that combines RAAS inhibition with the block of neprilysin, boosting the positive effects of natriuretic peptides. The PARADIGM-HF trial demonstrated a significant advantage of sacubitril/valsartan over enal...
Source: European Journal of Internal Medicine - April 26, 2022 Category: Internal Medicine Authors: Pasquale Perrone-Filardi Stefania Paolillo Piergiuseppe Agostoni Christian Basile Cristina Basso Francesco Barill à Michele Correale Antonio Curcio Massimo Mancone Marco Merlo Marco Metra Saverio Muscoli Savina Nodari Alberto Palazzuoli Roberto Pedrinell Source Type: research

Renin-angiotensin-aldosterone system inhibition in patients affected by heart failure: efficacy, mechanistic effects and practical use of sacubitril/valsartan. Position Paper of the Italian Society of Cardiology
Eur J Intern Med. 2022 Apr 22:S0953-6205(22)00142-X. doi: 10.1016/j.ejim.2022.04.006. Online ahead of print.ABSTRACTRenin-angiotensin-aldosterone system (RAAS) inhibition is a mainstay of the pharmacological treatment of heart failure with reduced ejection fraction (HFrEF). In the last years RAAS blockade has been improved by the introduction of the Angiotensin Receptor-Neprilysin Inhibitor (ARNI) sacubitril/valsartan, that combines RAAS inhibition with the block of neprilysin, boosting the positive effects of natriuretic peptides. The PARADIGM-HF trial demonstrated a significant advantage of sacubitril/valsartan over enal...
Source: European Journal of Internal Medicine - April 26, 2022 Category: Internal Medicine Authors: Pasquale Perrone-Filardi Stefania Paolillo Piergiuseppe Agostoni Christian Basile Cristina Basso Francesco Barill à Michele Correale Antonio Curcio Massimo Mancone Marco Merlo Marco Metra Saverio Muscoli Savina Nodari Alberto Palazzuoli Roberto Pedrinell Source Type: research

Antihypertensive effect of Mali-Nil surin rice bran hydrolysate and its mechanisms related to the EDHF-mediated vasorelaxation and L-type Ca < sup > 2+ < /sup > channel-mediated vasoconstriction in L-NAME hypertensive rats
This study investigated an antihypertensive effect of MRH and evaluated the mechanisms mediating this action in Nω-nitro-L-arginine-methyl ester (L-NAME)-induced hypertensive rats. Antihypertensive activity was determined in male rats orally administered with MRH (100 or 300 mg/kg) or enalapril (15 mg/kg) daily together with L-NAME (50 mg/kg/day) in drinking water, for 21 days. Concurrent oral treatment with MRH lowered the high blood pressure in the L-NAME-induced hypertensive rats. MRH treatment improved endothelial function and increased the endothelium-derived hyperpolarizing factor-mediated vasorelaxation in L-NAME h...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 24, 2022 Category: Drugs & Pharmacology Authors: Patchareewan Pannangpetch Panot Tangsucharit Ratthipha Thanaruksa Tunvaraporn Proongkhong Supawadee Srisuwan Direk Aekthammarat Source Type: research

Antihypertensive effect of Mali-Nil surin rice bran hydrolysate and its mechanisms related to the EDHF-mediated vasorelaxation and L-type Ca < sup > 2+ < /sup > channel-mediated vasoconstriction in L-NAME hypertensive rats
This study investigated an antihypertensive effect of MRH and evaluated the mechanisms mediating this action in Nω-nitro-L-arginine-methyl ester (L-NAME)-induced hypertensive rats. Antihypertensive activity was determined in male rats orally administered with MRH (100 or 300 mg/kg) or enalapril (15 mg/kg) daily together with L-NAME (50 mg/kg/day) in drinking water, for 21 days. Concurrent oral treatment with MRH lowered the high blood pressure in the L-NAME-induced hypertensive rats. MRH treatment improved endothelial function and increased the endothelium-derived hyperpolarizing factor-mediated vasorelaxation in L-NAME h...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - April 24, 2022 Category: Drugs & Pharmacology Authors: Patchareewan Pannangpetch Panot Tangsucharit Ratthipha Thanaruksa Tunvaraporn Proongkhong Supawadee Srisuwan Direk Aekthammarat Source Type: research

GSE188349 Transcriptomic response in the heart and kidney to different types of antihypertensive drug administration [kidney]
Contributors : Fumihiko Takeuchi ; Norihiro KatoSeries Type : Expression profiling by arrayOrganism : Rattus norvegicusTo unravel antihypertensive drug-induced gene expression changes that are potentially related to the amelioration of end-organ damages, we performed in vivo phenotypic evaluation and transcriptomic analysis on the heart and the kidney, with administration of antihypertensive drugs to two inbred strains of (i.e., hypertensive and normotensive) rats. We chose to use six antihypertensive classes: enalapril (angiotensin converting enzyme inhibitor), candesartan (angiotensin receptor blocker), hydrochlorothia...
Source: GEO: Gene Expression Omnibus - April 15, 2022 Category: Genetics & Stem Cells Tags: Expression profiling by array Rattus norvegicus Source Type: research

GSE188348 Transcriptomic response in the heart and kidney to different types of antihypertensive drug administration [heart]
Contributors : Fumihiko Takeuchi ; Norihiro KatoSeries Type : Expression profiling by arrayOrganism : Rattus norvegicusTo unravel antihypertensive drug-induced gene expression changes that are potentially related to the amelioration of end-organ damages, we performed in vivo phenotypic evaluation and transcriptomic analysis on the heart and the kidney, with administration of antihypertensive drugs to two inbred strains of (i.e., hypertensive and normotensive) rats. We chose to use six antihypertensive classes: enalapril (angiotensin converting enzyme inhibitor), candesartan (angiotensin receptor blocker), hydrochlorothia...
Source: GEO: Gene Expression Omnibus - April 15, 2022 Category: Genetics & Stem Cells Tags: Expression profiling by array Rattus norvegicus Source Type: research

Effects of Sacubitril/Valsartan Versus Telmisartan in Type 2 Diabetic or Pre-Diabetic Patients with Hypertension and Without Heart Failure: The Rationale and Design of A Randomized Clinical Trial
CONCLUSION: All analyses will be performed based on the intention-to-treat principle among all randomized participants.PMID:35400328 | DOI:10.2174/1871529X22666220408223329 (Source: Cardiovascular and Hematological Disorders Drug Targets)
Source: Cardiovascular and Hematological Disorders Drug Targets - April 11, 2022 Category: Drugs & Pharmacology Authors: Ming-Tsung Sun Tsung-Jui Wu Yu-Kai Lin Yen-Po Lin Yun-Chen Chang Gen-Min Lin Source Type: research

Sacubitril/Valsartan Off-Label Uses for Heart Failure
Sacubitril/valsartan (S/V) is an angiotensin receptor-neprilysin inhibitor (ARNI), Food and Drug Administration (FDA) indicated to reduce the risk of cardiovascular (CV) death and hospitalization in patients with left ventricular ejection fraction (LVEF) below normal, with no specified LVEF cut-off.1 The Prospective Comparison of ARNI with angiotensin converting enzyme inhibitors (ACE-I) to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial showed sacubitril/valsartan's superiority over enalapril in patients with chronic heart failure (HF) with reduced EF. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - April 8, 2022 Category: Cardiology Authors: Kazuhiko Kido, Bailey M. Colvin, Thomas W. Szymanski, Maya Guglin Source Type: research

Enalapril/furosemide
(Source: Reactions Weekly)
Source: Reactions Weekly - April 1, 2022 Category: Drugs & Pharmacology Source Type: research